Summit Financial Wealth Advisors LLC Has $2.80 Million Holdings in Pfizer Inc. (NYSE:PFE)

Summit Financial Wealth Advisors LLC grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 36.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 107,012 shares of the biopharmaceutical company's stock after buying an additional 28,815 shares during the quarter. Summit Financial Wealth Advisors LLC's holdings in Pfizer were worth $2,804,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the fourth quarter worth $26,000. Rialto Wealth Management LLC bought a new position in shares of Pfizer in the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $28,000. Noble Wealth Management PBC acquired a new position in Pfizer during the fourth quarter valued at approximately $31,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Pfizer during the 4th quarter worth approximately $33,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on PFE. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. UBS Group dropped their price objective on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 8th. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of "Moderate Buy" and an average price target of $31.07.

Remove Ads

Pfizer Price Performance

Pfizer stock traded up $0.03 during trading hours on Monday, reaching $21.94. 30,808,000 shares of the stock were exchanged, compared to its average volume of 40,201,220. The stock has a 50 day moving average of $25.25 and a two-hundred day moving average of $26.38. The company has a market cap of $124.43 billion, a P/E ratio of 15.56, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 earnings per share. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.